ReviewFrontiers in pharmacology2025
A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-World Luspatercept Evidence in Myelodysplastic Neoplasms: A Systematic Review and Bayesian Meta-Analysis.Hematological oncology · 2026Pooled it
- Choosing real-world data for clinical and epidemiological research: methodological lessons from NHIRD and TriNetX-A narrative review.Annals of medicine · 2026Review
- Effectiveness of live-attenuated and inactivated influenza vaccines against influenza in 2-17-y-old children, United States, 2022-2025.Human vaccines & immunotherapeutics · 2026Article
- Patients with cervical degenerative disease have greater post-operative opioid use and reoperation following shoulder instability procedures.JSES reviews, reports, and techniques · 2026Article
- TriNetX LATAM Collaborative Network, an EHR Data Source in Latin America.Pharmacoepidemiology and drug safety · 2026Article
- The Psychiatric Comorbidities in Adolescents With Atopic Dermatitis: A Real-World Study of Propensity-Matched Cohorts.International journal of dermatology · 2026Article
- Prescribing Trajectories in Type 2 Diabetes in the United States, 2019-2024.Diabetes, obesity & metabolism · 2026Article
- Venous and arterial thrombosis following extracorporeal photopheresis: A descriptive cohort study using a federated electronic health record network.Transfusion · 2026Article
- Association of a Reported Penicillin Allergy Label With Clinical Outcomes in Alcohol-Associated Liver Disease.Alcohol, clinical & experimental research · 2026Article
- Long-term cardiovascular risks in patients with hypertensive disorders of pregnancy treated with nifedipine or labetalol.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Musculoskeletal Outcomes of Glucagon-Like Peptide-1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults.Obesity (Silver Spring, Md.) · 2026Article
- Parosmia Beyond Olfactory Loss: A Propensity Score-Matched Study of Central Sensitization-Associated Comorbidities.International forum of allergy & rhinology · 2026Article
- When One Plus One Does Not Equal Two: Embracing the Dynamic and Living Nature of Real-World Evidence.International journal of rheumatic diseases · 2026Article
- Mortality, cardiovascular disease, and cancer in coeliac disease and dermatitis herpetiformis: a matched cohort study.Lancet regional health. Americas · 2026Article
- Mildly Elevated Preoperative Inflammatory Markers and Postoperative Complications Following Total Knee Arthroplasty: A Propensity-Matched Cohort Analysis.Arthroplasty today · 2026Article
- Mechanical Thrombectomy Versus Anticoagulation in Intermediate-Risk Pulmonary Embolism: A Risk-Stratified, Propensity Score-Matched Analysis.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
- Implementation science and the clinical trial workforce: A national needs assessment of training and practice.Contemporary clinical trials communications · 2026Article
- Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men.EBioMedicine · 2026Article
- Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study.Hepatology international · 2026Observational
- Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Randomized controlled trials (RCTs) are the gold standard for evaluating the efficacy and safety of both pharmacological and non-pharmacological interventions. However, while they are designed to control confounders and ensure internal validity, their usually stringent inclusion and exclusion criteria often limit the generalizability of findings to broader patient populations. Moreover, RCTs are resource-intensive, frequently underpowered to detect rare adverse events, and sometimes narrowly focused due to their highly controlled environments. In contrast, real-world data (RWD), typically derived from electronic health records (EHRs) and claims databases, offers a valuable counterpart for answering research questions that may be impractical to address through RCTs. Recognizing this, the US Food and Drug Administration (FDA) has increasingly relied on real-world evidence (RWE) from RWD to support regulatory decisions and post-market surveillance. Platforms like TriNetX, that leverage large-scale RWD, facilitate collaborations between academia, industry, and healthcare organizations, and constitute an in-depth tool for retrieval and analysis of RWD. TriNetX's federated network architecture allows real-time, privacy-compliant data access, significantly enhancing the ability to conduct retrospective studies and refine clinical trial designs. With access to currently over 150 million EHRs, TriNetX has proven particularly effective in filling gaps left by RCTs, especially in the context of rare diseases, rare endpoints, and diverse patient populations. As the role of RWD in healthcare continues to expand, TriNetX stands out as a critical tool that complements traditional clinical trials, bridging the gap between controlled research environments and real-world practice. This review provides a comprehensive analysis of the methodologies and applications of the TriNetX platform, highlighting its potential contribution to advance patient care and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.